Incidence of Liver and Non-liver Cancers After Hepatitis C Virus Eradication: A Population-Based Cohort Study.
Jose RíosVíctor SapenaZoe MariñoJordi BruixXavier FornsRosa Morros-PedrosMaria ReigFerràn TorresCaridad PontesPublished in: Drugs - real world outcomes (2024)
Results showed that overall cancer and hepatocellular carcinoma incidence in Catalonia was significantly higher among HCV-treated patients compared with matched non-HCV-infected controls, and risks were higher in patients with cirrhosis. An increased awareness of the potential occurrence of uncommon malignant events and monitoring after HCV eradication therapy may benefit patients.
Keyphrases
- hepatitis c virus
- end stage renal disease
- newly diagnosed
- human immunodeficiency virus
- ejection fraction
- chronic kidney disease
- prognostic factors
- risk assessment
- squamous cell carcinoma
- stem cells
- mesenchymal stem cells
- helicobacter pylori
- human health
- patient reported outcomes
- antiretroviral therapy
- cell therapy